Literature DB >> 28164090

MET: roles in epithelial-mesenchymal transition and cancer stemness.

Hye-Min Jeon1, Jeongwu Lee1.   

Abstract

In a number of cancers, deregulated MET pathway leads to aberrantly activated proliferative and invasive signaling programs that promote malignant transformation, cell motility and migration, angiogenesis, survival in hypoxia, and invasion. A better understanding of oncogenic MET signaling will help us to discover effective therapeutic approaches and to identify which tumors are likely to respond to MET-targeted cancer therapy. In this review, we will summarize the roles of MET signaling in cancer, with particular focus on epithelial-mesenchymal transition (EMT) and cancer stemness. Then, we will provide update on MET targeting agents and discuss the challenges that should be overcome for the development of an effective therapy.

Entities:  

Keywords:  MET; cancer stem cell (CSC); epithelial-mesenchymal transition (EMT)

Year:  2017        PMID: 28164090      PMCID: PMC5253283          DOI: 10.21037/atm.2016.12.67

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  119 in total

1.  Wild-type p53 controls cell motility and invasion by dual regulation of MET expression.

Authors:  Chang-Il Hwang; Andres Matoso; David C Corney; Andrea Flesken-Nikitin; Stefanie Körner; Wei Wang; Carla Boccaccio; Snorri S Thorgeirsson; Paolo M Comoglio; Heiko Hermeking; Alexander Yu Nikitin
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-09       Impact factor: 11.205

2.  A novel role of hepatocyte growth factor as an immune regulator through suppressing dendritic cell function.

Authors:  Katsuhide Okunishi; Makoto Dohi; Kazuyuki Nakagome; Ryoichi Tanaka; Shinya Mizuno; Kunio Matsumoto; Jun-Ichi Miyazaki; Toshikazu Nakamura; Kazuhiko Yamamoto
Journal:  J Immunol       Date:  2005-10-01       Impact factor: 5.422

3.  Tumor-stromal cell interaction under hypoxia increases the invasiveness of pancreatic cancer cells through the hepatocyte growth factor/c-Met pathway.

Authors:  Takao Ide; Yoshihiko Kitajima; Atsushi Miyoshi; Takao Ohtsuka; Mayumi Mitsuno; Kazuma Ohtaka; Yasuo Koga; Kohji Miyazaki
Journal:  Int J Cancer       Date:  2006-12-15       Impact factor: 7.396

4.  Direct interaction of focal adhesion kinase (FAK) with Met is required for FAK to promote hepatocyte growth factor-induced cell invasion.

Authors:  Shu-Yi Chen; Hong-Chen Chen
Journal:  Mol Cell Biol       Date:  2006-07       Impact factor: 4.272

5.  Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung Cancer.

Authors:  David R Spigel; Martin J Edelman; Tony Mok; Kenneth O'Byrne; Luis Paz-Ares; Wei Yu; Karen Rittweger; Holger Thurm
Journal:  Clin Lung Cancer       Date:  2012-11       Impact factor: 4.785

6.  Essential role of BCL9-2 in the switch between beta-catenin's adhesive and transcriptional functions.

Authors:  Felix H Brembeck; Thomas Schwarz-Romond; Jeroen Bakkers; Sabine Wilhelm; Matthias Hammerschmidt; Walter Birchmeier
Journal:  Genes Dev       Date:  2004-09-01       Impact factor: 11.361

Review 7.  Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase.

Authors:  C Birchmeier; E Gherardi
Journal:  Trends Cell Biol       Date:  1998-10       Impact factor: 20.808

8.  Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor.

Authors:  Y Uehara; O Minowa; C Mori; K Shiota; J Kuno; T Noda; N Kitamura
Journal:  Nature       Date:  1995-02-23       Impact factor: 49.962

9.  Treatment rationale and study design for a randomized, double-blind, placebo-controlled phase II study evaluating onartuzumab (MetMAb) in combination with bevacizumab plus mFOLFOX-6 in patients with previously untreated metastatic colorectal cancer.

Authors:  Johanna C Bendell; Thomas J Ervin; David Gallinson; Jaswinder Singh; James A Wallace; Mansoor N Saleh; Marcy Vallone; See-Chun Phan; Stephen P Hack
Journal:  Clin Colorectal Cancer       Date:  2013-06-27       Impact factor: 4.481

10.  HGF converts ErbB2/Neu epithelial morphogenesis to cell invasion.

Authors:  Hanane Khoury; Monica A Naujokas; Dongmei Zuo; Veena Sangwan; Melanie M Frigault; Stephanie Petkiewicz; David L Dankort; William J Muller; Morag Park
Journal:  Mol Biol Cell       Date:  2004-11-17       Impact factor: 4.138

View more
  25 in total

1.  Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors.

Authors:  Amita Patnaik; Shirish Gadgeel; Kyriakos P Papadopoulos; Drew W Rasco; Naomi B Haas; Hirak Der-Torossian; Demiana Faltaos; Diane Potvin; Vanessa Tassell; Manal Tawashi; Richard Chao; Peter J O'Dwyer
Journal:  Target Oncol       Date:  2022-03-28       Impact factor: 4.864

Review 2.  The Roles of Nitric Oxide Synthase/Nitric Oxide Pathway in the Pathology of Vascular Dementia and Related Therapeutic Approaches.

Authors:  Han-Yan Zhu; Fen-Fang Hong; Shu-Long Yang
Journal:  Int J Mol Sci       Date:  2021-04-26       Impact factor: 5.923

Review 3.  The role of tumor microenvironment in resistance to anti-angiogenic therapy.

Authors:  Shaolin Ma; Sunila Pradeep; Wei Hu; Dikai Zhang; Robert Coleman; Anil Sood
Journal:  F1000Res       Date:  2018-03-15

4.  Immunophenotyping and transcriptional profiling of in vitro cultured human adipose tissue derived stem cells.

Authors:  Alina Mieczkowska; Adriana Schumacher; Natalia Filipowicz; Anna Wardowska; Maciej Zieliński; Piotr Madanecki; Ewa Nowicka; Paulina Langa; Milena Deptuła; Jacek Zieliński; Karolina Kondej; Alicja Renkielska; Patrick G Buckley; David K Crossman; Michael R Crowley; Artur Czupryn; Piotr Mucha; Paweł Sachadyn; Łukasz Janus; Piotr Skowron; Sylwia Rodziewicz-Motowidło; Mirosława Cichorek; Michał Pikuła; Arkadiusz Piotrowski
Journal:  Sci Rep       Date:  2018-07-27       Impact factor: 4.379

5.  BPI-9016M, a c-Met inhibitor, suppresses tumor cell growth, migration and invasion of lung adenocarcinoma via miR203-DKK1.

Authors:  Panpan Zhang; Shaolei Li; Chao Lv; Jiahui Si; Ying Xiong; Lieming Ding; Yuanyuan Ma; Yue Yang
Journal:  Theranostics       Date:  2018-11-12       Impact factor: 11.556

6.  Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells.

Authors:  Tony Navas; Thomas D Pfister; Simona Colantonio; Amina Aziz; Lynda Dieckman; Richard G Saul; Jan Kaczmarczyk; Suzanne Borgel; Sergio Y Alcoser; Melinda G Hollingshead; Young H Lee; Donald P Bottaro; Tara Hiltke; Gordon Whiteley; Naoko Takebe; Robert J Kinders; Ralph E Parchment; Joseph E Tomaszewski; James H Doroshow
Journal:  PLoS One       Date:  2018-06-21       Impact factor: 3.240

Review 7.  HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence.

Authors:  Jianjiang Fu; Xiaorui Su; Zhihua Li; Ling Deng; Xiawei Liu; Xuancheng Feng; Juan Peng
Journal:  Oncogene       Date:  2021-06-18       Impact factor: 9.867

8.  Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial.

Authors:  Toni K Choueiri; Daniel Y C Heng; Jae Lyun Lee; Mathilde Cancel; Remy B Verheijen; Anders Mellemgaard; Lone H Ottesen; Melanie M Frigault; Anne L'Hernault; Zsolt Szijgyarto; Sabina Signoretti; Laurence Albiges
Journal:  JAMA Oncol       Date:  2020-08-01       Impact factor: 31.777

Review 9.  Extracellular Matrix Influencing HGF/c-MET Signaling Pathway: Impact on Cancer Progression.

Authors:  Heydi Noriega-Guerra; Vanessa Morais Freitas
Journal:  Int J Mol Sci       Date:  2018-10-24       Impact factor: 5.923

10.  Integrated Analysis of Genomic and Immunological Features in Lung Adenocarcinoma With Micropapillary Component.

Authors:  Shirong Zhang; Yang Xu; Pan Zhao; Hua Bao; Xiyong Wang; Rui Liu; Rujun Xu; Jingjing Xiang; Hong Jiang; Junrong Yan; Xue Wu; Yang Shao; Jiafeng Liang; Qiong Wu; Zhihao Zhang; Shun Lu; Shenglin Ma
Journal:  Front Oncol       Date:  2021-06-17       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.